Back to News
Market Impact: 0.35
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Source: GlobeNewswire
Healthcare & BiotechRegulation & Legislation
MAIA received FDA clearance for its amended investigational new drug (IND) submission. The clearance highlights improvements in the company’s manufacturing capabilities and operating efficiencies, supporting continued clinical development progress.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
MAIA0.65
More News
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution
- Binance’s $6.3 billion hack raises questions about crypto wallet safety
- Hong Kong telecom company agrees to halt U.S. operations under pressure
- Crypto industry pours more than $200 million into 2026 midterms to pressure Congress on favorable rules
- Judge allows NAACP lawsuit over xAI data center pollution to move forward
- France braces for fresh unrest, government vows tough response